BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

HemoCue Prevails In Patent Infringement Suit


3/14/2006 11:40:34 AM

Angelholm, SWEDEN, March 14 /PRNewswire/ -- For more than two years, HemoCue AB and EKF-diagnostics GmbH, a company in Magdeburg, Germany, have been involved in a patent infringement suit. The patent in dispute is licensed to HemoCue AB, a pioneer in point-of-care testing. The Dusseldorf District Court where the German patent infringement case has been tried, announced its ruling on March 9. The Court found that the EKF product infringes HemoCue's patent, registered in 1995. The product, with near worldwide patent protection, is a Swedish invention and an established standard in near-patient hemoglobin testing globally. From a single drop of capillary blood, the product determines the concentration of hemoglobin -- a test used to diagnose acute blood loss, detect anemia and screen blood donors.

According to HemoCue's CEO, Thomas Glanzmann, this is an important victory providing a decisive first instance ruling on an issue included also in other legal proceedings. The Court in Dusseldorf is one of the leading patent courts in Europe and considered one of the most experienced and proficient in this area.

HemoCue will initiate preliminary enforcement of the Court's decision. Once in place, no further sales or manufacturing of the infringing cuvette will be permissible.

"We spend a lot of time and money on protecting our proprietary rights and will continue to do so," says Clas Runnberg, responsible for legal processes at HemoCue. "For years, we are making considerable efforts in research and development of new products. These are based on our own innovations and involve unique technology, and that requires sizeable investments. Ensuring the best patent protection possible is therefore an obvious priority. The court ruling today shows that this protection, in spite of the long wait, has a value."

For additional product information, please call contact below or visit < http://www.hemocue.com >.

HemoCue is a leading global company in a field of diagnostic testing known as point-of-care testing. In 1982, the company introduced the first system making accurate hemoglobin testing possible outside the hospital environment. The system consists of an instrument and a disposable microcuvette used with each test. Since then, HemoCue has installed more than 200,000 systems worldwide, which are being used to deliver about 100 million tests each year.

HemoCue

CONTACT: Clas Runnberg, Head of Corporate Affairs of HemoCue AB, +46 43145 82 70, clas.runnberg@hemocue.se



Read at BioSpace.com

HemoCue
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES